T1	Participants 96 117	head-and-neck cancer.
T2	Participants 242 276	patients with head-and-neck cancer
T3	Participants 300 314	Fifty patients
T4	Participants 702 777	acute and late nonhematologic toxicities (mucositis, dysphagia, xerostomia)
T5	Participants 966 990	amifostine-treated group
T6	Participants 1144 1168	amifostine-treated group
T7	Participants 2101 2134	patients with head-and-neck cance
